BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 20124218)

  • 21. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
    Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
    Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA-TG and risk of sinusoidal obstruction syndrome in childhood acute lymphoblastic leukemia.
    Toksvang LN; Grell K; Nielsen SN; Nersting J; Murdy D; Moorman AV; Vora A; Schmiegelow K
    Leukemia; 2022 Feb; 36(2):555-557. PubMed ID: 34535761
    [No Abstract]   [Full Text] [Related]  

  • 23. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial.
    Lauer SJ; Shuster JJ; Mahoney DH; Winick N; Toledano S; Munoz L; Kiefer G; Pullen JD; Steuber CP; Camitta BM
    Leukemia; 2001 Jul; 15(7):1038-45. PubMed ID: 11455971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Lauer SJ; Camitta BM; Leventhal BG; Mahoney DH; Shuster JJ; Adair S; Casper JT; Civin CI; Graham M; Kiefer G
    Cancer; 1993 May; 71(9):2854-61. PubMed ID: 8467463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
    Schmiegelow K; Al-Modhwahi I; Andersen MK; Behrendtz M; Forestier E; Hasle H; Heyman M; Kristinsson J; Nersting J; Nygaard R; Svendsen AL; Vettenranta K; Weinshilboum R;
    Blood; 2009 Jun; 113(24):6077-84. PubMed ID: 19224761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?
    Lennard L; Davies HA; Lilleyman JS
    Br J Cancer; 1993 Jul; 68(1):186-90. PubMed ID: 8318412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group.
    Matloub Y; Rabin KR; Ji L; Devidas M; Hitzler J; Xu X; Bostrom BC; Stork LC; Winick N; Gastier-Foster JM; Heerema NA; Stonerock E; Carroll WL; Hunger SP; Gaynon PS
    Blood Adv; 2019 Jun; 3(11):1647-1656. PubMed ID: 31160295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.
    Landier W; Hageman L; Chen Y; Kornegay N; Evans WE; Bostrom BC; Casillas J; Dickens DS; Angiolillo AL; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Relling MV; Wong FL; Bhatia S
    J Clin Oncol; 2017 May; 35(15):1730-1736. PubMed ID: 28339328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
    Schmiegelow K; Bretton-Meyer U
    Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report.
    Kaleita TA; Reaman GH; MacLean WE; Sather HN; Whitt JK
    Cancer; 1999 Apr; 85(8):1859-65. PubMed ID: 10223582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia.
    Larsen RH; Utke Rank C; Grell K; Nørgaard Møller L; Malthe Overgaard U; Kampmann P; Nersting J; Degn M; Nygaard Nielsen S; Holst H; Klug Albertsen B; Skov Wehner P; Thude Callesen M; Kanerva J; Leth Frandsen T; Als-Nielsen B; Lyngsie Hjalgrim L; Schmiegelow K
    Haematologica; 2021 Nov; 106(11):2824-2833. PubMed ID: 34047177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ocular hemorrhage secondary to thioguanine-associated veno-occlusive disease in a child with acute lymphoblastic leukemia in delayed intensification.
    Bhunia N; Yeager ND; Colace SI; Buzzaco D; Bajwa RPS
    Pediatr Transplant; 2020 Feb; 24(1):e13638. PubMed ID: 31840375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.
    Brandalise SR; Pinheiro VR; Aguiar SS; Matsuda EI; Otubo R; Yunes JA; Pereira WV; Carvalho EG; Cristofani LM; Souza MS; Lee ML; Dobbin JA; Pombo-de-Oliveira MS; Lopes LF; Melnikoff KN; Brunetto AL; Tone LG; Scrideli CA; Morais VL; Viana MB
    J Clin Oncol; 2010 Apr; 28(11):1911-8. PubMed ID: 20212252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
    Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
    Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TPMT and MTHFR genotype is not associated with altered risk of thioguanine-related sinusoidal obstruction syndrome in pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Wray L; Vujkovic M; McWilliams T; Cannon S; Devidas M; Stork L; Aplenc R
    Pediatr Blood Cancer; 2014 Nov; 61(11):2086-8. PubMed ID: 24737678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sinusoidal Obstruction Syndrome During Maintenance Therapy for Acute Lymphoblastic Leukemia With 6-Mercaptopurine and Methotrexate: A Pediatric Case Report.
    McNerney KO; Vasquez JC; Kent MW; McNamara JM
    J Pediatr Hematol Oncol; 2017 Nov; 39(8):e454-e455. PubMed ID: 28085749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
    Lange BJ; Blatt J; Sather HN; Meadows AT
    Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
    Dervieux T; Brenner TL; Hon YY; Zhou Y; Hancock ML; Sandlund JT; Rivera GK; Ribeiro RC; Boyett JM; Pui CH; Relling MV; Evans WE
    Blood; 2002 Aug; 100(4):1240-7. PubMed ID: 12149204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: A protocol for systematic review and meta-analysis.
    Chen L; Yan HX; Liu XW; Chen WX
    Medicine (Baltimore); 2020 May; 99(18):e20082. PubMed ID: 32358392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Palliative cytoreduction in refractory acute leukemia: a retrospective study of 57 adult patients.
    Funke I; Wiesneth M; Platow S; Kubanek B
    Ann Hematol; 2000 Mar; 79(3):132-7. PubMed ID: 10803935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.